Understanding AMETHYST Design and Patient Needs in CLE

Despite affecting millions of people worldwide, cutaneous lupus erythematosus (CLE) has long posed a clinical challenge that extends beyond diagnosis. For patients with moderate to severe disease, particularly those who are refractory or intolerant to antimalarial therapy, treatment options remain limited, and the consequences of inadequately controlled disease are not merely cosmetic.

Scarring, alopecia, and dyspigmentation can be permanent, disfiguring, and deeply damaging to quality of life. Selecting endpoints that capture this reality, rather than simply measuring biological activity, is central to evaluating whether a new therapy can meaningfully move the needle for this population.

The AMETHYST Phase 2/3 study evaluated litifilimab, an investigational monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells, in participants with active subacute or chronic CLE who had failed or could not tolerate antimalarials. The Phase 2 portion of the study employed 2 primary instruments: the CLA-IGA-R, which assessed clear or almost clear skin at Week 16, and the CLASI, a validated composite measure of disease activity and damage that has become a standard tool in CLE clinical research.

CLASI-50 and CLASI-70 thresholds, representing 50% and 70% reductions in disease activity from baseline, respectively, served as key secondary endpoints, and at Week 24, 1 in 6 participants receiving litifilimab achieved a CLASI score of 0 to 3, defined as no or minimal disease activity, compared with none in the placebo group.¹

These endpoints matter because they align with what patients and clinicians are actually trying to achieve: not incremental reduction in erythema scores, but meaningful, visible, and sustained clearance of skin disease in a patient population accustomed to inadequate responses. The speed of separation, with differences emerging as early as Week 4 on CLASI-50, adds further clinical context to the efficacy signal.

In this segment, Joseph Merola, MD, MMSc, and Victoria Werth, MD, discuss why the endpoint selection in AMETHYST reflects the true burden of CLE, what the observed response thresholds mean in the context of daily clinical practice, and how these data begin to address a treatment gap that has persisted for more than seven decades.

References

1. Biogen Inc. Biogen announces second positive Phase 2 litifilimab trial in cutaneous lupus erythematosus at 2026 American Academy of Dermatology Annual Meeting, showing a significant reduction in skin disease activity. Published March 28, 2026. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial